How the body processes Vepdegestrant in liver impairment
This study tests how the drug Vepdegestrant is processed by people with different levels of liver function. It aims to understand if liver problems change how the drug works, which can help doctors give the right dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You weigh more than 110 pounds (50 kg)
- Your body mass index (BMI) is between 17.5 and 38
- If you have healthy liver function, you must be generally healthy with no major medical issues
- If you have liver problems, your liver impairment must be stable for at least 28 days before the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how the body processes the drug velzatinib in people with different levels of liver function, compared to those with healthy livers. The results may help doctors determine the right dose for people with liver problems.
This is an early-stage study testing a new medicine called PF-08653944 in healthy adults and in people with varying degrees of liver function problems. The goal is to understand how the medicine works in the body and how liver function affects how the body processes it.
This study looks at how mirdametinib is processed in people with liver problems compared to healthy people. It will help doctors understand if the dose needs to be adjusted.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This trial tests how the drug vorasidenib behaves in people with severe liver problems compared to healthy volunteers. It helps doctors understand if the drug needs different dosing for patients with liver disease.
This trial tests how a new medicine, LY3537031, moves through the body and how safe it is for people with different levels of liver function. It includes people with normal livers and those with mild, moderate, or severe liver impairment.
Hear when a new Healthy Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.